Cell biologists at the Ruhr-Universitšt Bochum (RUB) have launched a new project to unravel the role of the enzyme Parkin in promoting neuronal survival. The team of Prof Dr Konstanze F. Winklhofer from the Institute of Physiological Chemistry, Department of Molecular Cell Biology, is looking for new therapeutic options to treat Parkinson's disease. The Michael J. Fox Foundation finances this research project with 125,000 US Dollars.
Parkin activates a signal pathway that protects neurons
Parkinson's disease is characterized by the degeneration of neurons that produce the neurotransmitter dopamine. In some cases, mutations in the Parkin gene are the underlying cause of this disease. The RUB researchers have recently discovered that Parkin regulates a signal pathway that protects neurons under cellular stress from damage. When the integrity of mitochondria, the cell's powerhouses, is impaired, Parkin is recruited to a protein complex called LUBAC (linear ubiquitin chain assembly complex) and increases its activity. A signal pathway is then activated that leads to the increased expression of protective factors, thus preventing cell death. The RUB team investigates the molecular mechanism of how parkin activates LUBAC and which other regulators play a role in this process. The goal of the project is to identify novel targets to halt or delay the neurodegenerative process in Parkinson's disease.
Prof Dr Konstanze Winklhofer, Institute of Physiological Chemistry, Faculty of Medicine at the Ruhr-Universitšt, 44780 Bochum, Germany, phone +49/234/32-22428, email: firstname.lastname@example.org
Editor: Dr Julia Weiler
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.